Leveraging more than a decade of excellence in immuno-oncology, Dr. Borin Scutti has earned distinction as the lead director of thoracic malignancies for Bristol Myers Squibb.
DOUGLASSVILLE, PA, March 09, 2023 /24-7PressRelease/ -- Jorge Augusto Borin Scutti, MSc, PhD, has been included in Marquis Who's Who. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.
Leveraging more than a decade of excellence in immuno-oncology, Dr. Borin Scutti has earned distinction as the lead director of thoracic malignancies for Bristol Myers Squibb (BMS). Since 2018, he has focused his efforts on planning and driving strategy for medical affairs, speaking and working with physicians to best address patients' needs while providing support to help patients with cancer to understand their treatment options.
Prior to his current role, Dr. Borin Scutti began his career working in scientific initiation for the Universidade Estadual Paulista in 2006 and was an application scientist for AD Instruments in 2009. He then was the chief executive officer of Cancer Focus from 2011 until 2013, which was originally created to develop and implement projects and programs involving immuno-oncology, cancer immunology and immunotherapy as the central theme. He also was a visiting professor of pathology, hematology, lab test interpretation and clinical immunology for Senac, São Paulo and served as associate professor for Complexo Educacional FMU, Laureate from 2011 until 2014.
In 2015, Dr. Borin Scutti continued his distinguished career earning a post-doc at MD Anderson Cancer Center (MDACC). In the same year, he joined the Immunotherapy Platform (IMT) and served as a research scientist, earning a promotion to a senior research scientist in 2017. During his tenure at MDACC and IMT, he had the privilege to drive force along with top-notch scientist, including the 2015 Albert and Mary Foundation (Lasker-DeBakey) and 2018 Nobel Prize Dr. James Allison, the scientist who opened up a new way to treat cancer by unleashing the immune system to attack it. The IMT provides MD Anderson investigators with support for immunotherapies in the treatment of a wide variety of tumor types and helps to link immunologic data with the genomic and proteomic platforms for several clinical trials.
The next year, he joined Merck and served as the associate director, medical affairs strategy lead for biomarkers and diagnostics and took a role in 2020 as the director of biomarkers and diagnostics for the US Health System Oncology team.
Dr. Borin Scutti joined Bristol Myers Squibb in 2021 as the director lead of thoracic malignancies and became the interim executive director for thoracic malignancies, ABRAXANE and emerging tumors later that year. Additionally, he was a scientist writer for the Houston Medical Times, contributing his own articles to a variety of professional journals.
Among his professional accomplishments, Dr. Borin Scutti is proud to have received an honorable mention from Araraquara University in 2006 for his study in an underprivileged community to identify endoparasites in children. He was honored with more than 60 indications in the "For Ways of Working Award" from Merck and was the PhD-Level winner of Best Scientific Research by the Brazilian Society of Immunology in 2010. He also was awarded the "You can count on me" Award by Merck and the Emperor Science Award by Stand Up to Cancer in 2016 and 2017.
Prior to embarking on his professional journey, Dr. Borin Scutti earned a bachelor's degree in biomedical science in 2008, a master's in microbiology and immunology in 2010 from the Federal University of São Paulo (UNIFESP) in Brazil. He then attained a Doctor of Philosophy from the same institution in 2012. In the lab, Dr. Borin Scutti worked in the field of cancer immunology, immunotherapy and cell biology with a special emphasis on exploring the most advanced gene targeting technologies to silencing genes and discovering peptides (immunogenic and adjuvant peptides) as candidates for cancer vaccines, including melanoma and lung. He was directly involved in the bioactivity of internal peptides of transcription factors and the design of more efficient new generation of cancer vaccines centering on immune-active peptides and dendritic cells. He completed a postdoctoral fellowship at the MD Anderson Cancer Center in 2015 which consisted in immunotherapy based on Natural Killer cells (NK) and Diffuse Intrinsic Pontine Glioma (DIPG), a rare high grade glial tumor that occurs in young children and is uniformly fatal.
Within the coming years, Dr. Borin Scutti intends to continue leading the strategic aspect of medical, scientific affairs and clinical development. As a leader, his goal is to keep others engaged, inspiring them to continue to be dedicated to their work and rise to leadership positions themselves. Passionate and committed to his profession, he considers his patients his utmost priority and will persevere to solve their problems. He is inspired by his own experiences as an immigrant from a non-English speaking country, which drives him to help others as much as possible.
About Marquis Who's Who®:
Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America®, Marquis Who's Who® has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Marquis celebrates its 125th anniversary in 2023, and Who's Who in America® remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. Marquis® publications may be visited at the official Marquis Who's Who® website at www.marquiswhoswho.com.
# # #